Published in J Biol Chem on September 19, 2002
The role of COX-2 in intestinal inflammation and colorectal cancer. Oncogene (2009) 2.72
The distinct roles of cyclooxygenase-1 and -2 in neuroinflammation: implications for translational research. Trends Pharmacol Sci (2009) 1.84
Enzymes of the cyclooxygenase pathways of prostanoid biosynthesis. Chem Rev (2011) 1.67
Structural basis for induced formation of the inflammatory mediator prostaglandin E2. Proc Natl Acad Sci U S A (2008) 1.58
Endocannabinoid oxygenation by cyclooxygenases, lipoxygenases, and cytochromes P450: cross-talk between the eicosanoid and endocannabinoid signaling pathways. Chem Rev (2011) 1.56
Endocannabinoid metabolism and uptake: novel targets for neuropathic and inflammatory pain. Br J Pharmacol (2007) 1.39
The expanding field of cannabimimetic and related lipid mediators. Br J Pharmacol (2005) 1.38
The glyceryl ester of prostaglandin E2 mobilizes calcium and activates signal transduction in RAW264.7 cells. Proc Natl Acad Sci U S A (2004) 1.36
Prostanoid receptor antagonists: development strategies and therapeutic applications. Br J Pharmacol (2009) 1.31
Cyclooxygenase-2 in synaptic signaling. Curr Pharm Des (2008) 1.26
Non-redundant functions of cyclooxygenases: oxygenation of endocannabinoids. J Biol Chem (2008) 1.26
PGE2 glycerol ester, a COX-2 oxidative metabolite of 2-arachidonoyl glycerol, modulates inhibitory synaptic transmission in mouse hippocampal neurons. J Physiol (2006) 1.25
Lipidomic analysis of endocannabinoid metabolism in biological samples. J Chromatogr B Analyt Technol Biomed Life Sci (2009) 1.23
Prostamides (prostaglandin-ethanolamides) and their pharmacology. Br J Pharmacol (2007) 1.23
The structural basis of endocannabinoid oxygenation by cyclooxygenase-2. J Biol Chem (2011) 1.16
Endocannabinoid 2-arachidonoylglycerol protects neurons by limiting COX-2 elevation. J Biol Chem (2008) 1.15
The contribution of cyclooxygenase-2 to endocannabinoid metabolism and action. Br J Pharmacol (2007) 1.14
Are cannabidiol and Δ(9) -tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review. Br J Pharmacol (2015) 1.12
Ethanolamide oxylipins of linolenic acid can negatively regulate Arabidopsis seedling development. Plant Cell (2013) 1.12
The endocannabinoid anandamide is a substrate for the human polymorphic cytochrome P450 2D6. J Pharmacol Exp Ther (2008) 1.12
Eicosanoid regulation of hematopoiesis and hematopoietic stem and progenitor trafficking. Leukemia (2010) 1.09
Oxidation of the endogenous cannabinoid arachidonoyl ethanolamide by the cytochrome P450 monooxygenases: physiological and pharmacological implications. Pharmacol Rev (2010) 1.05
Endocannabinoid signalling: has it got rhythm? Br J Pharmacol (2010) 1.04
Critical enzymes involved in endocannabinoid metabolism. Protein Pept Lett (2007) 1.04
Endocannabinoid signalling and the deteriorating brain. Nat Rev Neurosci (2015) 1.03
The endogenous cannabinoid, anandamide, induces cell death in colorectal carcinoma cells: a possible role for cyclooxygenase 2. Gut (2005) 1.00
Identification of an antagonist that selectively blocks the activity of prostamides (prostaglandin-ethanolamides) in the feline iris. Br J Pharmacol (2006) 0.99
The endocannabinoid system: an overview. Front Behav Neurosci (2012) 0.99
Zymosan-induced glycerylprostaglandin and prostaglandin synthesis in resident peritoneal macrophages: roles of cyclo-oxygenase-1 and -2. Biochem J (2006) 0.97
COX-2 oxidative metabolism of endocannabinoids augments hippocampal synaptic plasticity. Mol Cell Neurosci (2008) 0.97
Loss of cannabinoid receptor CB1 induces preterm birth. PLoS One (2008) 0.96
Dynamic changes to the endocannabinoid system in models of chronic pain. Philos Trans R Soc Lond B Biol Sci (2012) 0.96
Substrate-selective COX-2 inhibition as a novel strategy for therapeutic endocannabinoid augmentation. Trends Pharmacol Sci (2014) 0.95
Anandamide reduces infarct size in rat isolated hearts subjected to ischaemia-reperfusion by a novel cannabinoid mechanism. Br J Pharmacol (2005) 0.95
Alcohol dehydrogenase-catalyzed in vitro oxidation of anandamide to N-arachidonoyl glycine, a lipid mediator: synthesis of N-acyl glycinals. Bioorg Med Chem Lett (2008) 0.95
"Redundancy" of endocannabinoid inactivation: new challenges and opportunities for pain control. ACS Chem Neurosci (2012) 0.93
Glucocorticoids shift arachidonic acid metabolism toward endocannabinoid synthesis: a non-genomic anti-inflammatory switch. Eur J Pharmacol (2008) 0.93
Lack of effect of chronic pre-treatment with the FAAH inhibitor URB597 on inflammatory pain behaviour: evidence for plastic changes in the endocannabinoid system. Br J Pharmacol (2012) 0.93
Conformationally constrained analogues of 2-arachidonoylglycerol. Bioorg Med Chem Lett (2007) 0.92
Differential regulation of endocannabinoid synthesis and degradation in the uterus during embryo implantation. Prostaglandins Other Lipid Mediat (2006) 0.92
Monoacylglycerol lipase - a target for drug development? Br J Pharmacol (2012) 0.91
New families of bioactive oxidized phospholipids generated by immune cells: identification and signaling actions. Blood (2012) 0.91
Altered GABAergic neurotransmission is associated with increased kainate-induced seizure in prostaglandin-endoperoxide synthase-2 deficient mice. Brain Res Bull (2007) 0.90
Regulation of gonadotropin-releasing hormone secretion by cannabinoids. Endocrinology (2005) 0.90
Design and synthesis of (13S)-methyl-substituted arachidonic acid analogues: templates for novel endocannabinoids. Chemistry (2010) 0.90
Neuropharmacology of the endocannabinoid signaling system-molecular mechanisms, biological actions and synaptic plasticity. Curr Neuropharmacol (2007) 0.90
Cellular basis for bimatoprost effects on human conventional outflow. Invest Ophthalmol Vis Sci (2010) 0.89
Human platelets generate phospholipid-esterified prostaglandins via cyclooxygenase-1 that are inhibited by low dose aspirin supplementation. J Lipid Res (2013) 0.89
β-Amyloid exacerbates inflammation in astrocytes lacking fatty acid amide hydrolase through a mechanism involving PPAR-α, PPAR-γ and TRPV1, but not CB₁ or CB₂ receptors. Br J Pharmacol (2012) 0.87
Combined inhibition of FAAH and COX produces enhanced anti-allodynic effects in mouse neuropathic and inflammatory pain models. Pharmacol Biochem Behav (2014) 0.85
Esterified eicosanoids: generation, characterization and function. Biochim Biophys Acta (2011) 0.85
Role of prostaglandins and specific place in therapy of bimatoprost in the treatment of elevated intraocular pressure and ocular hypertension: A closer look at the agonist properties of bimatoprost and the prostamides. Clin Ophthalmol (2009) 0.85
Production and actions of the anandamide metabolite prostamide E2 in the renal medulla. J Pharmacol Exp Ther (2012) 0.85
Tempo and mode in the endocannaboinoid system. J Mol Evol (2007) 0.84
Structural determinants for calcium mobilization by prostaglandin E2 and prostaglandin F2alpha glyceryl esters in RAW 264.7 cells and H1819 cells. Prostaglandins Other Lipid Mediat (2010) 0.84
Endocannabinoid system: emerging role from neurodevelopment to neurodegeneration. Mini Rev Med Chem (2009) 0.84
Receptor-dependent and receptor-independent endocannabinoid signaling: a therapeutic target for regulation of cancer growth. Life Sci (2012) 0.84
Lipidomics profile of a NAPE-PLD KO mouse provides evidence of a broader role of this enzyme in lipid metabolism in the brain. Biochim Biophys Acta (2016) 0.82
15-Deoxy-delta12,14-prostaglandin J2-glycerol ester, a putative metabolite of 2-arachidonyl glycerol, activates peroxisome proliferator activated receptor gamma. Mol Pharmacol (2011) 0.82
What we know and do not know about the cannabinoid receptor 2 (CB2). Semin Immunol (2014) 0.81
Arachidonoyl ethanolamide (AEA)-induced apoptosis is mediated by J-series prostaglandins and is enhanced by fatty acid amide hydrolase (FAAH) blockade. Mol Carcinog (2011) 0.81
A shifted repertoire of endocannabinoid genes in the zebrafish (Danio rerio). Mol Genet Genomics (2007) 0.81
In vivo pharmacology of endocannabinoids and their metabolic inhibitors: therapeutic implications in Parkinson's disease and abuse liability. Prostaglandins Other Lipid Mediat (2009) 0.81
Increased angiotensin II contraction of the uterine artery at early gestation in a transgenic model of hypertensive pregnancy is reduced by inhibition of endocannabinoid hydrolysis. Hypertension (2014) 0.81
2-Arachidonoyl-glycerol- and arachidonic acid-stimulated neutrophils release antimicrobial effectors against E. coli, S. aureus, HSV-1, and RSV. J Leukoc Biol (2012) 0.81
Lipidomic metabolism analysis of the endogenous cannabinoid anandamide (N-arachidonylethanolamide). J Pharm Biomed Anal (2010) 0.80
Care and feeding of the endocannabinoid system: a systematic review of potential clinical interventions that upregulate the endocannabinoid system. PLoS One (2014) 0.80
Prostaglandin H synthase-2-catalyzed oxygenation of 2-arachidonoylglycerol is more sensitive to peroxide tone than oxygenation of arachidonic acid. J Biol Chem (2012) 0.79
Competition and allostery govern substrate selectivity of cyclooxygenase-2. Proc Natl Acad Sci U S A (2015) 0.79
Depletion of iNOS-derived nitric oxide by prostaglandin H synthase-2 in inflammation-activated J774.2 macrophages through lipohydroperoxidase turnover. Biochem J (2005) 0.79
Identification of prostamides, fatty acyl ethanolamines, and their biosynthetic precursors in rabbit cornea. J Lipid Res (2015) 0.78
Microsomal omega-hydroxylated metabolites of N-arachidonoyl dopamine are active at recombinant human TRPV1 receptors. Prostaglandins Other Lipid Mediat (2008) 0.78
Quantitative LC-MS/MS analysis of arachidonoyl amino acids in mouse brain with treatment of FAAH inhibitor. Anal Biochem (2012) 0.78
Cyclooxygenase-2, prostaglandin E2 glycerol ester and nitric oxide are involved in muscarine-induced presynaptic enhancement at the vertebrate neuromuscular junction. J Physiol (2013) 0.78
Brain region-specific changes in N-acylethanolamine contents with time of day. J Neurochem (2013) 0.78
Broad impact of deleting endogenous cannabinoid hydrolyzing enzymes and the CB1 cannabinoid receptor on the endogenous cannabinoid-related lipidome in eight regions of the mouse brain. Pharmacol Res (2016) 0.77
Oxidized PLs and vascular inflammation. Curr Atheroscler Rep (2013) 0.77
Enantioselective synthesis of (10S)- and (10R)-methyl-anandamides. Tetrahedron (2012) 0.77
The gastrointestinal tract - a central organ of cannabinoid signaling in health and disease. Neurogastroenterol Motil (2016) 0.77
WWL70 attenuates PGE2 production derived from 2-arachidonoylglycerol in microglia by ABHD6-independent mechanism. J Neuroinflammation (2017) 0.76
Fetal Alcohol Spectrum Disorder: Potential Role of Endocannabinoids Signaling. Brain Sci (2015) 0.76
Inhibition of endocannabinoid metabolism by the metabolites of ibuprofen and flurbiprofen. PLoS One (2014) 0.76
Bimatoprost effects on aqueous humor dynamics in monkeys. J Ophthalmol (2010) 0.76
Endocannabinoid Signaling in Autism. Neurotherapeutics (2015) 0.76
The endocannabinoid system as a target for novel anxiolytic drugs. Neurosci Biobehav Rev (2017) 0.75
Involvement of the endocannabinoid system in the physiological response to transient common carotid artery occlusion and reperfusion. Lipids Health Dis (2017) 0.75
4'-O-methylhonokiol increases levels of 2-arachidonoyl glycerol in mouse brain via selective inhibition of its COX-2-mediated oxygenation. J Neuroinflammation (2015) 0.75
Metabolism of Anandamide by Human Cytochrome P450 2J2 in the Reconstituted System and Human Intestinal Microsomes. J Pharmacol Exp Ther (2016) 0.75
Global deletion of MGL in mice delays lipid absorption and alters energy homeostasis and diet-induced obesity. J Lipid Res (2015) 0.75
Dual-Acting Compounds Targeting Endocannabinoid and Endovanilloid Systems-A Novel Treatment Option for Chronic Pain Management. Front Pharmacol (2016) 0.75
Lipidomic Analysis of Endocannabinoid Signaling: Targeted Metabolite Identification and Quantification. Neural Plast (2015) 0.75
Protective Action of Anandamide and Its COX-2 Metabolite against l-Homocysteine-Induced NLRP3 Inflammasome Activation and Injury in Podocytes. J Pharmacol Exp Ther (2016) 0.75
NSAIDs, Opioids, Cannabinoids and the Control of Pain by the Central Nervous System. Pharmaceuticals (Basel) (2010) 0.75
Design and synthesis of novel prostaglandin E2 ethanolamide and glycerol ester probes for the putative prostamide receptor(s). Tetrahedron Lett (2015) 0.75
Metabolism of the Endocannabinoid Anandamide: Open Questions after 25 Years. Front Mol Neurosci (2017) 0.75
Prostaglandin E2 glyceryl ester is an endogenous agonist of the nucleotide receptor P2Y6. Sci Rep (2017) 0.75
Accelerated telomere shortening in response to life stress. Proc Natl Acad Sci U S A (2004) 12.89
Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science (2005) 5.12
Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin. J Clin Invest (2012) 4.31
A low dose of dietary resveratrol partially mimics caloric restriction and retards aging parameters in mice. PLoS One (2008) 3.25
Cellular mechanisms of redox cell signalling: role of cysteine modification in controlling antioxidant defences in response to electrophilic lipid oxidation products. Biochem J (2004) 3.15
Impaired inflammatory and pain responses in mice lacking an inducible prostaglandin E synthase. Proc Natl Acad Sci U S A (2003) 2.80
Membrane prostaglandin E synthase-1: a novel therapeutic target. Pharmacol Rev (2007) 2.75
The relationship between dose of vitamin E and suppression of oxidative stress in humans. Free Radic Biol Med (2007) 2.62
Quantification of F2-isoprostanes as a biomarker of oxidative stress. Nat Protoc (2007) 2.56
Quantification of the major urinary metabolite of PGE2 by a liquid chromatographic/mass spectrometric assay: determination of cyclooxygenase-specific PGE2 synthesis in healthy humans and those with lung cancer. Anal Biochem (2004) 2.24
Selective cyclooxygenase-1 and -2 inhibitors each increase allergic inflammation and airway hyperresponsiveness in mice. Am J Respir Crit Care Med (2002) 2.17
Cyclooxygenases: structural and functional insights. J Lipid Res (2008) 2.14
Factors associated with oxidative stress in human populations. Am J Epidemiol (2002) 2.13
Interaction of electrophilic lipid oxidation products with mitochondria in endothelial cells and formation of reactive oxygen species. Am J Physiol Heart Circ Physiol (2005) 2.12
Lipid peroxidation in aging brain and Alzheimer's disease. Free Radic Biol Med (2002) 2.08
Levels of prostaglandin E metabolite and leukotriene E(4) are increased in the urine of smokers: evidence that celecoxib shunts arachidonic acid into the 5-lipoxygenase pathway. Cancer Prev Res (Phila) (2009) 2.06
Quantification of F2-isoprostanes in biological fluids and tissues as a measure of oxidant stress. Methods Enzymol (2007) 1.98
Mechanism of free radical oxygenation of polyunsaturated fatty acids by cyclooxygenases. Chem Rev (2003) 1.93
Angiotensin II induces interleukin-6 in humans through a mineralocorticoid receptor-dependent mechanism. Hypertension (2006) 1.91
Opposite effects of cyclooxygenase-1 and -2 activity on the pressor response to angiotensin II. J Clin Invest (2002) 1.86
Fatty acid amide hydrolase deficiency limits early pregnancy events. J Clin Invest (2006) 1.86
Malondialdehyde, a product of lipid peroxidation, is mutagenic in human cells. J Biol Chem (2003) 1.86
Identification of protein targets of 4-hydroxynonenal using click chemistry for ex vivo biotinylation of azido and alkynyl derivatives. Chem Res Toxicol (2008) 1.82
Contribution of cyclooxygenase-2 to elevated biosynthesis of thromboxane A2 and prostacyclin in cigarette smokers. Circulation (2005) 1.82
Peripheral F2-isoprostanes and F4-neuroprostanes are not increased in Alzheimer's disease. Ann Neurol (2002) 1.79
Selective vulnerability of preterm white matter to oxidative damage defined by F2-isoprostanes. Ann Neurol (2005) 1.77
Structural and functional basis of cyclooxygenase inhibition. J Med Chem (2007) 1.75
Novel n-3 fatty acid oxidation products activate Nrf2 by destabilizing the association between Keap1 and Cullin3. J Biol Chem (2006) 1.70
A novel mechanism of cyclooxygenase-2 inhibition involving interactions with Ser-530 and Tyr-385. J Biol Chem (2003) 1.69
Fluorinated COX-2 inhibitors as agents in PET imaging of inflammation and cancer. Cancer Prev Res (Phila) (2011) 1.68
Enzymes of the cyclooxygenase pathways of prostanoid biosynthesis. Chem Rev (2011) 1.67
Selective visualization of cyclooxygenase-2 in inflammation and cancer by targeted fluorescent imaging agents. Cancer Res (2010) 1.66
Human biochemistry of the isoprostane pathway. J Biol Chem (2008) 1.63
Isoprostanes and related products of lipid peroxidation in neurodegenerative diseases. Chem Phys Lipids (2004) 1.63
Cyclooxygenase-2 promotes early atherosclerotic lesion formation in LDL receptor-deficient mice. Circulation (2002) 1.62
Prospective study of urinary prostaglandin E2 metabolite and colorectal cancer risk. J Clin Oncol (2006) 1.62
Differential sensitivity and mechanism of inhibition of COX-2 oxygenation of arachidonic acid and 2-arachidonoylglycerol by ibuprofen and mefenamic acid. Biochemistry (2009) 1.61
Structural basis for induced formation of the inflammatory mediator prostaglandin E2. Proc Natl Acad Sci U S A (2008) 1.58
Endogenous reactive intermediates as modulators of cell signaling and cell death. Chem Res Toxicol (2006) 1.57
Endocannabinoid oxygenation by cyclooxygenases, lipoxygenases, and cytochromes P450: cross-talk between the eicosanoid and endocannabinoid signaling pathways. Chem Rev (2011) 1.56
Ibuprofen use, endotoxemia, inflammation, and plasma cytokines during ultramarathon competition. Brain Behav Immun (2006) 1.54
Determinants of the cellular specificity of acetaminophen as an inhibitor of prostaglandin H(2) synthases. Proc Natl Acad Sci U S A (2002) 1.54
Circulating neutrophils maintain physiological blood pressure by suppressing bacteria and IFNgamma-dependent iNOS expression in the vasculature of healthy mice. Blood (2008) 1.53
Cyclooxygenase-1 is overexpressed and promotes angiogenic growth factor production in ovarian cancer. Cancer Res (2003) 1.53
Aberrant cannabinoid signaling impairs oviductal transport of embryos. Nat Med (2004) 1.52
Systems analysis of protein modification and cellular responses induced by electrophile stress. Acc Chem Res (2010) 1.51
Antioxidant vitamins C and E improve endothelial function in children with hyperlipidemia: Endothelial Assessment of Risk from Lipids in Youth (EARLY) Trial. Circulation (2003) 1.49
Lipid peroxidation is an early event in the brain in amnestic mild cognitive impairment. Ann Neurol (2005) 1.49
Alterations in gene expression induced by the lipid peroxidation product, 4-hydroxy-2-nonenal. Chem Res Toxicol (2005) 1.47
Vitamin E and immunity after the Kona Triathlon World Championship. Med Sci Sports Exerc (2004) 1.47
Multiplex analyses of antibodies against citrullinated peptides in individuals prior to development of rheumatoid arthritis. Arthritis Rheum (2013) 1.46
Microsomal prostaglandin E synthase-1 is the central switch during immune-induced pyresis. Nat Neurosci (2003) 1.45
F2-isoprostanes as markers of oxidative stress in vivo: an overview. Biomarkers (2005) 1.44
Neuronal oxidative damage from activated innate immunity is EP2 receptor-dependent. J Neurochem (2002) 1.44
The isoprostanes: unique products of arachidonic acid oxidation-a review. Curr Med Chem (2003) 1.44
15-Lipoxygenase metabolism of 2-arachidonylglycerol. Generation of a peroxisome proliferator-activated receptor alpha agonist. J Biol Chem (2002) 1.43
Centralized oversight of physician-scientist faculty development at Vanderbilt: early outcomes. Acad Med (2008) 1.42
Cancer-associated immunodeficiency and dendritic cell abnormalities mediated by the prostaglandin EP2 receptor. J Clin Invest (2003) 1.42
Heat shock factor 1 attenuates 4-Hydroxynonenal-mediated apoptosis: critical role for heat shock protein 70 induction and stabilization of Bcl-XL. J Biol Chem (2007) 1.40
Human microsomal prostaglandin E synthase-1: purification, functional characterization, and projection structure determination. J Biol Chem (2003) 1.39
(R)-Profens are substrate-selective inhibitors of endocannabinoid oxygenation by COX-2. Nat Chem Biol (2011) 1.39
HSF1-mediated BAG3 expression attenuates apoptosis in 4-hydroxynonenal-treated colon cancer cells via stabilization of anti-apoptotic Bcl-2 proteins. J Biol Chem (2009) 1.39
Molecular basis of the time-dependent inhibition of cyclooxygenases by indomethacin. Biochemistry (2004) 1.37
Cyclooxygenase-1 is a potential target for prevention and treatment of ovarian epithelial cancer. Cancer Res (2005) 1.36
The glyceryl ester of prostaglandin E2 mobilizes calcium and activates signal transduction in RAW264.7 cells. Proc Natl Acad Sci U S A (2004) 1.36
Lipid profiling reveals arachidonate deficiency in RAW264.7 cells: Structural and functional implications. Biochemistry (2006) 1.36
Oxidative stress and matrix metalloproteinase-9 in acute ischemic stroke: the Biomarker Evaluation for Antioxidant Therapies in Stroke (BEAT-Stroke) study. Stroke (2007) 1.35
Fish oil increases cholesterol storage in white adipose tissue with concomitant decreases in inflammation, hepatic steatosis, and atherosclerosis in mice. J Nutr (2007) 1.35
Lack of integrin alpha1beta1 leads to severe glomerulosclerosis after glomerular injury. Am J Pathol (2004) 1.33
MYC inhibition induces metabolic changes leading to accumulation of lipid droplets in tumor cells. Proc Natl Acad Sci U S A (2013) 1.33
DASH diet lowers blood pressure and lipid-induced oxidative stress in obesity. Hypertension (2003) 1.32
Rescue of female infertility from the loss of cyclooxygenase-2 by compensatory up-regulation of cyclooxygenase-1 is a function of genetic makeup. J Biol Chem (2003) 1.32
Urine PGE-M: A metabolite of prostaglandin E2 as a potential biomarker of advanced colorectal neoplasia. Clin Gastroenterol Hepatol (2006) 1.32
Repeated homotypic stress elevates 2-arachidonoylglycerol levels and enhances short-term endocannabinoid signaling at inhibitory synapses in basolateral amygdala. Neuropsychopharmacology (2009) 1.29
Neuroprotective effects of the triterpenoid, CDDO methyl amide, a potent inducer of Nrf2-mediated transcription. PLoS One (2009) 1.29
A phase II study of celecoxib in combination with paclitaxel, carboplatin, and radiotherapy for patients with inoperable stage IIIA/B non-small cell lung cancer. Clin Cancer Res (2009) 1.27
Electrophilic cyclopentenone neuroprostanes are anti-inflammatory mediators formed from the peroxidation of the omega-3 polyunsaturated fatty acid docosahexaenoic acid. J Biol Chem (2008) 1.26
Oxidative metabolism of endocannabinoids by COX-2. Curr Pharm Des (2004) 1.26
Non-redundant functions of cyclooxygenases: oxygenation of endocannabinoids. J Biol Chem (2008) 1.26
Colon carcinoma cell growth is associated with prostaglandin E2/EP4 receptor-evoked ERK activation. J Biol Chem (2004) 1.26
Induction of frameshift and base pair substitution mutations by the major DNA adduct of the endogenous carcinogen malondialdehyde. Proc Natl Acad Sci U S A (2003) 1.25
Formation of F-ring isoprostane-like compounds (F3-isoprostanes) in vivo from eicosapentaenoic acid. J Biol Chem (2006) 1.25
Targeting cyclooxygenase-2 in recurrent non-small cell lung cancer: a phase II trial of celecoxib and docetaxel. Clin Cancer Res (2005) 1.23
The lipoxygenase gene ALOXE3 implicated in skin differentiation encodes a hydroperoxide isomerase. Proc Natl Acad Sci U S A (2003) 1.22
Molecular basis for cyclooxygenase inhibition by the non-steroidal anti-inflammatory drug naproxen. J Biol Chem (2010) 1.22
Acetylcholine-induced endothelium-dependent contractions in the SHR aorta: the Janus face of prostacyclin. Br J Pharmacol (2005) 1.21
Characterization of LPS-induced lung inflammation in cftr-/- mice and the effect of docosahexaenoic acid. J Appl Physiol (1985) (2002) 1.20
Intraindividual variability of plasma antioxidants, markers of oxidative stress, C-reactive protein, cotinine, and other biomarkers. Epidemiology (2006) 1.19
Age-related impairment of the transcriptional responses to oxidative stress in the mouse heart. Physiol Genomics (2003) 1.19
Amino acid determinants in cyclooxygenase-2 oxygenation of the endocannabinoid anandamide. Biochemistry (2003) 1.19
Relations of glycemic index and glycemic load with plasma oxidative stress markers. Am J Clin Nutr (2006) 1.18
Expression of COX-2 in platelet-monocyte interactions occurs via combinatorial regulation involving adhesion and cytokine signaling. J Clin Invest (2006) 1.18
A phase I trial to determine the optimal biological dose of celecoxib when combined with erlotinib in advanced non-small cell lung cancer. Clin Cancer Res (2006) 1.18
Control of prostaglandin stereochemistry at the 15-carbon by cyclooxygenases-1 and -2. A critical role for serine 530 and valine 349. J Biol Chem (2001) 1.17